Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Immunotherapy acquired resistance was observed in clinical practice. The investigators
intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.